bpi tirzepatide Labs BPI Labs challenges tirzepatide patent,

The most commonly prescribed medications in this category include semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound), which are FDA-approved specifically for chronic weight management

Semaglutide (Wegovy): Designed for weight loss, clinical trials show an average reduction of 1520% of body weight over 612 months with proper diet and exercise

You may qualify if you have a BMI of 25 or greater

Gambero et al The positive effects of yerba mat in obesity. HACK: Eriocitrin lemon extract: Nutraceutical eriocitrin (Eriomin) reduces hyperglycemia by increasing glucagon-like peptide 1 and downregulates systemic inflammation: a crossover-randomized clinical trial. Journal of medicinal food 25.11 (2022)